- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03014895
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects
November 12, 2018 updated by: EA Pharma Co., Ltd.
A Randomized, Double-blind, Placebo-controlled, Single Intravenous Ascending Dose Study of E3112 in Japanese Healthy Adult Male Subjects
The study (E3112/CP1) is a single-center, randomized, double-blind, placebo-controlled, single intravenous ascending dose study conducted in Japanese healthy adult males to evaluate the pharmacokinetics (PK), safety, and immunogenicity of E3112 following a single intravenous dose of E3112.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Toshima, Tokyo, Japan
- EA Pharma Trial Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 44 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Main Inclusion Criteria:
- Non-smoking, Japanese, male participants, ≥20 and <45 years old at the time of obtaining informed consent
- Have a Body Mass Index (BMI) ≥18.5 and <25.0 kilograms per meters squared (kg/m^2) at Screening
- Able to provide written informed consent of their free will
- Males who were given a full explanation of all the requirements of the protocol, and are willing and able to comply with them
Exclusion Criteria:
Main Exclusion Criteria:
- Male and his partner who do not agree to use a highly effective method of contraception throughout the entire study period, if he has reproductive capacity
- Male who had or has any malignant tumor, lymphoma, leukaemia, or lymphoproliferative disorders. Clinically significant illness that required medical treatment within 8 weeks or a clinically significant infection within 4 weeks prior to dosing.
- Evidence of disease that may influence the outcome of the study within 4 weeks prior to dosing
- Any history of surgical treatment that may affect pharmacokinetic (PK) profiles of study drug at Screening
- Any suspected clinically abnormal symptom or organ impairment that require medical treatment at Screening or Baseline
- Receipt of vaccination within 4 weeks prior to dosing
- History of drug or alcohol dependency or abuse prior to Screening
- Intake of caffeinated beverages or food within 72 hours prior to dosing
- Use of prescription drugs within 4 weeks prior to dosing
- Intake of over-the-counter (OTC) medications within 2 weeks prior to dosing
- Male who is currently being enrolled in another clinical study or used any investigational drug or device in another clinical study within 16 weeks prior to dosing
- Male who underwent a blood transfusion within 12 weeks prior to dosing, who donate 400 milliliters (mL) or more of whole blood within 12 weeks prior to dosing, who donate 200 mL or more of whole blood within 4 weeks prior to dosing, or who made a component donation within 2 weeks prior to dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Cohort 1: Placebo
Intravenous placebo infusion
|
Intravenous infusion
|
Experimental: Cohort 1: E3112
Intravenous E3112 infusion
|
Intravenous infusion
|
Placebo Comparator: Cohort 2: Placebo
Intravenous placebo infusion
|
Intravenous infusion
|
Experimental: Cohort 2: E3112
Intravenous E3112 infusion
|
Intravenous infusion
|
Placebo Comparator: Cohort 3: Placebo
Intravenous placebo infusion
|
Intravenous infusion
|
Experimental: Cohort 3: E3112
Intravenous E3112 infusion
|
Intravenous infusion
|
Placebo Comparator: Cohort 4: Placebo
Intravenous placebo infusion
|
Intravenous infusion
|
Experimental: Cohort 4: E3112
Intravenous E3112 infusion
|
Intravenous infusion
|
Placebo Comparator: Cohort 5: Placebo
Intravenous placebo infusion
|
Intravenous infusion
|
Experimental: Cohort 5: E3112
Intravenous E3112 infusion
|
Intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak concentration (Cmax) of E3112
Time Frame: Days 1 to 4, 8, 14, and 28
|
Cmax is the maximum observed concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered.
|
Days 1 to 4, 8, 14, and 28
|
Time to peak concentration (Tmax) of E3112
Time Frame: Days 1 to 4, 8, 14, and 28
|
Tmax is the time from dosing to reach the maximum observed concentration a drug achieves in a specified compartment or test area of the body after the drug has been administered.
|
Days 1 to 4, 8, 14, and 28
|
Area under the curve (AUC)
Time Frame: Days 1 to 4, 8, 14, and 28
|
AUC is the area under the curve in a plot of concentration of drug in blood plasma against time.
AUC represents the total drug exposure over a defined period of time.
|
Days 1 to 4, 8, 14, and 28
|
Half-life of elimination (t1/2) of E3112
Time Frame: Days 1 to 4, 8, 14, and 28
|
t1/2 is the time required for the concentration of the drug to reach half of its original value.
|
Days 1 to 4, 8, 14, and 28
|
Clearance of E3112
Time Frame: Days 1 to 4, 8, 14, and 28
|
Clearance is defined as the rate of drug elimination divided by the plasma concentration of the drug.
|
Days 1 to 4, 8, 14, and 28
|
Volume of distribution (Vd) of E3112
Time Frame: Days 1 to 4, 8, 14, and 28
|
Vd is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma.
|
Days 1 to 4, 8, 14, and 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with any serious adverse event and any non-serious adverse event
Time Frame: Days 1 to 28
|
An adverse event is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
A serious adverse event is defined as any adverse event occurring at any dose that results in any of the following outcomes: results in death; is life threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life function; results in a congenital anomaly/birth defect; or can be defined as any other important medical event.
|
Days 1 to 28
|
Number of participants with an abnormal, clinically significant hematology parameter value
Time Frame: Days 1 to 28
|
Clinical significance will be determined by the investigator.
|
Days 1 to 28
|
Number of participants with an abnormal, clinically significant blood chemistry parameter value
Time Frame: Days 1 to 28
|
Clinical significance will be determined by the investigator.
|
Days 1 to 28
|
Number of participants with an abnormal, clinically significant urine value
Time Frame: Days 1 to 28
|
Clinical significance will be determined by the investigator.
|
Days 1 to 28
|
Number of participants with an abnormal, clinically significant vital sign measurement
Time Frame: Baseline; Days 1 to 28
|
Clinical significance will be determined by the investigator.
|
Baseline; Days 1 to 28
|
Number of participants with an abnormal, clinically significant electrocardiogram (ECG) measurement
Time Frame: Baseline; Days 1 to 28
|
Clinical significance will be determined by the investigator.
|
Baseline; Days 1 to 28
|
Number of participants with an abnormal, clinically significant physical examination measurement
Time Frame: Baseline; Days 1 to 28
|
Clinical significance will be determined by the investigator.
|
Baseline; Days 1 to 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 25, 2017
Primary Completion (Actual)
June 12, 2017
Study Completion (Actual)
November 22, 2017
Study Registration Dates
First Submitted
January 6, 2017
First Submitted That Met QC Criteria
January 6, 2017
First Posted (Estimate)
January 9, 2017
Study Record Updates
Last Update Posted (Actual)
November 14, 2018
Last Update Submitted That Met QC Criteria
November 12, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- E3112/CP1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Volunteers
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
PMV Pharmaceuticals, IncCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.UnknownHealthy Male VolunteersKorea, Republic of
-
Bristol-Myers SquibbCompletedHealthy Male VolunteersUnited States
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthy Male VolunteersKorea, Republic of
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Allist Pharmaceuticals, Inc.CompletedHealthy Male VolunteersChina
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States